Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials

Contemporary Clinical Trials

Volumn 31, Issue 6, 2010, Pages 572-578

  Mander, A P ^a   Thompson, S G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Optimal design; Phase II trials; Simon's two stage design; Two stage designs

Indexed keywords

ALTERNATIVE HYPOTHESIS; ARTICLE; CANCER RESEARCH; COMPUTER PROGRAM; NULL HYPOTHESIS; SAMPLE SIZE; STUDY DESIGN; TREATMENT RESPONSE;

CLINICAL TRIALS, PHASE II AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; NEOPLASMS; SAMPLE SIZE; SOFTWARE;

EID: 77957937857     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.07.008     Document Type: Article

References (20)

1. Girling D., Parmar M., Stenning S., Stephens R., Stewart L. Clinical trials in cancer: principles and practice 2003, Oxford University Press, Oxford. first ed.
2. Lee J., Feng L. Randomised phase II designs in cancer clinical trials: current status and future directions. Journal of Clinical Oncology 2005, 23:4450-4457.
3. Fleming T. One-sample multiple testing procedure for phase II clincal trials. Biometrics 1982, 38:143-151.
4. O'Brien P., Fleming T. A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-555.
5. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989, 10:1-10.
6. Chen K., Shan M. Optimal and minimax three-stage designs for phase II oncology clinical trials. Contemporary Clinical Trials 2008, 29:32-41.
7. Chen T. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine 1997, 16:2701-2711.
8. Jung S., Lee T., Kim K., George S. Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine 2004, 23:561-569.
9. Lee J., Liu D. A predictive probability design for phase II cancer clinical trials. Clinical Trials 2008, 5:93-106.
10. Ye F., Shyr Y. Balanced two-stage designs for phase II clinical trials. Clinical Trials 2007, 5:514-524.
11. Koyama T., Chen H. Proper inference from Simon's two-stage designs. Statistics in Medicine 2008, 27:3145-3154.
12. Lin Y., Shih W. Adaptive two-stage designs for single-arm phase IIA cancer clinical trials. Biometrics 2004, 60:482-490.
13. Stata statistical software: release 11 2009, StataCorp, StataCorp LP, College Station, TX.
14. Chi Y., Chen C.M. Curtailed two-stage designs in phase II clinical trials. Statistics in Medicine 2008, 27:6175-6189.
15. Sleijfer S., Ray-Coquard I., Papai Z., Le Cesne A., Scurr M., Schoffski P., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group. Journal of Clinical Oncology 2009, 27:3126-3132.
16. Simon R. How large should a phase II trial of a new drug be?. Cancer Treatment Reports 1987, 71:1079-1085.
17. Shuster J. Optimal two-stage designs for single arm phase II cancer trials. Journal of Biopharmaceutical Statistics 2002, 12:39-51.
18. Hanfelt J., Slack R., Gehan E. A modification of Simon's optimal design for phase II trials when the criterion is median sample size. Controlled Clinical Trials 1999, 20:555-566.
19. Ratain M., Eckhardt S. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. Journal of Clinical Oncology 2004, 22:4442-4445.
20. Chang M. Improved confidence intervals for a binomial parameter following a group sequential phase II clinical trial. Statistics in Medicine 2004, 23:2817-2826.